CRD-4730 clinical trials
CRD-4730 is named as an intervention in 2 current clinical trials in our USA, France, Spain, Italy, Netherlands and Canada registers. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is Cardurion Pharmaceuticals, Inc. The most-studied condition is Heart Failure With Reduced Ejection Fraction (HFrEF). The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for CRD-4730
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of CRD-4730
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899 · Catecholaminergic Polymorphic Ventricular Tachycardia
|
Phase 2 | Recruiting | Cardurion Pharmaceuticals, Inc | USA, France, Spain, Italy, Netherlands, Canada |
|
A Trial of CRD-4730 in HFrEF
NCT07750873 · Heart Failure With Reduced Ejection Fraction (HFrEF)
|
Phase 2 | Recruiting | Cardurion Pharmaceuticals, Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
CRD-4730 in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing CRD-4730. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)
(CALIBRATE-HF)
2025-525033-31-00 · Cardiovascular Diseases
|
Phase 2 | Authorised | Cardurion Pharmaceuticals Inc | Latvia, Slovakia, Lithuania + 7 more |
Conditions studied with CRD-4730
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Cardurion Pharmaceuticals, Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about CRD-4730 trials
How many clinical trials are testing CRD-4730?
2 current trials in our USA, France, Spain, Italy, Netherlands and Canada registers name CRD-4730 as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are CRD-4730 trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors CRD-4730 clinical trials?
The lead sponsor is Cardurion Pharmaceuticals, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CRD-4730 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CRD-4730 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CRD-4730 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.